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Introduction 
Chronic liver disease is responsible for over 1.4 million deaths annually  [1] and is characterized by 
permanent inflammatory processes that predispose to liver cancer and in particular hepatocellular 
carcinoma (HCC). In healthy liver, inflammatory processes stimulate growth and repair and restore 
normal liver architecture. However, if liver inflammation becomes chronic, the balance of damage 
versus regeneration in the liver is disrupted and can lead to the formation of excessive scar tissue, 
termed fibrosis. In the long-term, an exacerbation of fibrosis will lead to cirrhosis, which is 
characterized by abnormal liver architecture and function and is associated with a significant reduction 
in overall health and wellbeing. At cirrhotic stages, liver damage is often irreversible or difficult to 
treat. Cirrhosis leads frequently to death from liver failure or to HCC (Figure 1). Indeed, HCC is the 
first cause of death in cirrhotic patients [2], and is a tumor with poor prognosis, ranking third in terms 
of death by cancer. Furthermore, it is the fifth most prevalent cancer worldwide, with 800,000 new 
cases per year in the world [2,3].  
Figure 1. Liver disease progression overview. 
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An estimated 75% of all HCC cases are due to chronic infection with hepatitis B (HBV) or hepatitis 
C (HCV) viruses, and the incidence rate of HCC is predicted to increase in western countries until the 
2020s due to HCV infection [3,4]. Currently available HCC therapies, based on anticancerous agents, 
chemotherapy, surgical or radiation-based resection, are inefficient, mainly due to usually late 
diagnosis and high recurrence rates after surgical resection, and usually end with treatment failure 
(Figure 2). Liver transplantation also remains a difficult strategy in patients with HCC. Thus, 
prevention of HCC by treating and preventing HBV and HCV infection – the major causative agents of 
HCC – is of great medical importance, particularly in the light of 400 million chronic HBV and 
170 million chronic HCV carriers worldwide [3]. The fact that a major part of the worldwide HCC 
cases is due to infection with HBV or HCV warrants a better understanding of the life cycle and host-
cell interactions of these two viruses in order to allow the design of new rationalized therapeutic 
strategies aiming at improving prevention and patients’ treatment. Major issues in the future will be to 
answer key questions in the respective HCV, HBV and HCC fields in order to gain a comprehensive 
view of the situation: Why are these viruses so successful at establishing chronic infections and how 
do they modulate and escape innate and adaptive host-immune responses to do so? How can we restore 
efficient antiviral immunity and eliminate or control chronic infection? How can we prevent disease 
progression and treat HCC? This special issue discusses recent advances in our knowledge of the basic 
biology of HBV and HCV, how these viruses may establish chronic infection and cause liver damage 
and ultimately cancer in the long-term. Finally, an update of the treatment and therapeutics that are in 
development against these major human pathogens is given.  
Current limitations to the treatment of HBV and HCV 
Although a vaccine exists against HBV, it is not always available in developing countries for 
economical reasons. Antiviral treatments against HBV only keep the viral load low but do not 
eliminate the virus and thus favor the emergence of drug-resistant mutants, as discussed in detail in by 
Lampertico et al. and De Clercq et al. in reviews that focus on antiviral-treatment and -development, 
respectively. Concerning HCV, no vaccine will become available in the immediate future and the 
outlook seems dull, despite important progress over the last few years, as reviewed by M. Major. The 
therapeutic arsenal against HCV is based upon the use of interferon and ribavirin, a costly and difficult 
treatment to support, to which a significant proportion of the patients do not respond. With the 
development of novel antivirals that directly interfere with HCV, treatment options are advancing and 
treatment success is improving. However, despite the novel combination therapies that are now 
becoming available, and which are reviewed in detail by Delang et al. in this issue, overall viral 
resistance and non-response to treatment will remain critical issues for treatment of both HBV and 
HCV patients (Figure 2) [5,6]. Thus, a better understanding of the basic biology of these viruses and 
the development of novel therapeutic approaches remains an important issue.  
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Figure 2. Liver disease progression and treatment options. 
 
 
Chronic HBV and HCV infection and the pathological consequences  
Hepatitis B and C virus are members of two different viral families, but both display a strong 
hepatotropism, whose underlying molecular mechanisms are not yet entirely understood. HBV belongs 
to the family of hepadnaviridae, and Schaedler et al. give an overview of its life cycle in this issue. 
HBV contains a partially double stranded genomic DNA that does not encode a dominant oncogene. 
Thus, HBV is thought to be carcinogenic in an indirect fashion, such as by insertional activation of 
cellular oncogenes, the induction of genetic instability upon HBV DNA integration or by the 
regulatory protein HBx as well as by modulation of host immune reponses  [7].  
HCV is member of the flaviviridae, where it forms its own genus, Hepacivirus. HCV is a small, 
enveloped positive-sense, single stranded RNA virus, and its life cycle is thought to be predominantly 
cytoplasmic  [8]. Thus, HCV is likely to predispose to cancer by alteration of cell signaling and 
metabolism as well as by modulating and inducing immune responses  [9]. Modulation of cellular 
immunity and metabolism are processes that are likely to establish a liver microenvironment that is 
characterized by chronic inflammation, oxidative stress and repair processes that lead to liver fibrosis, 
cirrhosis and HCC over time [10]. In addition, some HCV proteins have been shown to alter cell 
proliferation and cell cycle checkpoint machineries as well [11,12]. 
The fact that both HCV and HBV manage to escape elimination by host innate and adaptive 
immune responses has been a focus of intensive research in many laboratories. Indeed, innate as well 
as adaptive immune responses of the host have been shown to be compromised by both viruses, albeit 
by different mechanisms. For a long time, HBV has been thought not to induce innate immunity at all. 
In this issue, Ait-goughoulte et al. discuss recent data sets obtained by several different laboratories 
that suggest that HBV is not necessarily a stealth virus, but can be sensed by the innate immune system 
and has rather evolved ways to blunt these responses. In respect to HCV, its ability to evade innate 
immunity at several levels in vitro has been well acknowledged in the field, and a review by Markus 
Heim in this issue presents the underlying molecular mechanisms.  Viruses 2010, 2                              
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The precise role of adaptive immune responses in the clinical outcomes of HBV and HCV infection 
are still only partially defined. Regarding HCV, recent studies suggest that the nature of the adaptive 
immune responses during the acute phase determine whether the virus is cleared or whether a chronic 
infection manifests itself. Two reviews, by Zeisel et al. and Bengtsch et al., summarize different 
aspects of the adaptive immune responses as determinants of the outcome of HCV infection and 
outline current concepts of the evasion strategies HCV may use to prevent its elimination. Unravelling 
these important mechanisms of virus-host interaction will contribute to the development of novel 
strategies to prevent and control HCV infection. Similarly to HCV infection, successful control of 
HBV infection requires activation of several arms of the adaptive immune system including B cells, 
helper and cytotoxic T cells. In addition, the role of the intrahepatic environment has been shown to 
modulate virus-specific immunity and has therefore become an important focus of research. Bertoletti 
et al. discuss how the liver environment and the network of immune as well as parenchymal and non-
parenchymal cells interact and communicate to achieve HBV clearance.  
Chronic activation of the immune system, as it is the case for HCV and HBV infections, creates 
oxidative stress via cytotoxic degradation of infected or damaged cells. It has been known for some 
time that HCV replication aggravates the oxidative microenvironment in the liver by additional 
mechanisms such as modulation of intracellular signaling cascades and metabolic pathways. Several 
lines of evidence suggest that HCV replication, assembly and entry are closely intertwined with and 
modulate the hepatic glucose, lipid and cholesterol metabolism [13,14]. Clinically, these modulations 
manifest themselves in the form of insulin resistance, fatty liver and hypobetalipoproteinemia [15]. 
Importantly, these pathologies are driven by, and in turn, augment oxidative stress and thus favor 
inflammation, fibrosis development and disease progression towards cirrhosis and HCC. Clement et al. 
shed light on the interplay between hepatic glucose and lipid metabolism, oxidative stress and 
inflammation, their potential roles in the HCV life cycle and in the associated pathologies, while a 
review by Bartosch et al. discusses the importance of lipids for HCV infection and the cell entry 
process in particular.  
Hepatocarcinogenesis 
Viral eradication is the most efficient strategy to reduce the risk of HCC development in HBV and 
HCV patients with chronic liver disease. However, this does not apply to patients who have already 
developed cirrhosis. Once cirrhosis has occurred, despite the eradication of the cause of liver disease, 
the risk of HCC is increased since cirrhosis is considered as a preneoplastic state. At this stage of the 
disease, efficient antiviral treatment decreases, but does not ablate the risk of HCC development [16]. 
The molecular mechanisms underlying hepatocarcinogenesis remain far from understood, including 
the responsible etiological factors, the marked genetic and epigenetic heterogeneity, as well as the cell 
types at the origin of transformation. A review by Benhenda et al. discusses the molecular mechanisms 
underlying hepatitis virus-induced hepatocarcinogenesis, while Merle et al., focus on oncogenic 
pathways that are activated particularly at late stages of the transformation process in virus and non-
virus induced hepatocarcinogenesis.  
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Limitations to the investigation of HBV and HCV 
A better understanding of the interactions between HBV and HCV and the hepatocytes as well as 
other liver resident cell types and the immune system is warranted in order to understand the 
pathologies associated with chronic hepatitis virus infection and how they may predispose to cancer. 
Two major obstacles hinder the investigation of HBV- and HCV-host cell interactions. The first is the 
fact that the liver is a highly specialized and structured organ, with physiological functions that depend 
on a defined liver architecture and proper cell differentiation and polarization. The recapitulation of 
these features in vitro is difficult, and thus in vitro replication systems for HBV and HCV have so far 
relied heavily on tissue culture adapted, transformed cell lines. Secondly, HBV and HCV display a 
liver tropism that is restricted to very few species apart from humans, which has made the development 
of animal model systems difficult. Meuleman et al. summarize the animal models that have been 
developed over the years and that have now become available to study HCV infection in vivo, and a 
review by Benhenda et al. mentions animal systems available for the study of HBV.  
Summary 
Hepatocarcinogenesis is, and will continue to be a major worldwide health problem. With chronic 
HBV and HCV infections being responsible for a significant proportion of HCC cases, the 
development of new and relevant cell culture and animal models to study the interactions of HBV and 
HCV with their host and the development of efficient means to combat chronic infections will remain 
major tasks to tackle. This special issue gives an overview of our current state of knowledge in respect 
to the basic biology of these viruses, as well as the clinical and therapeutic options that have been, and 
are being developed, and highlights the major current technical and biological limitations that the field 
needs to overcome.  
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